These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26701662)

  • 1. Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator.
    Nieddu E; Pollarolo B; Mazzei MT; Anzaldi M; Schenone S; Pedemonte N; Galietta LJ; Mazzei M
    Arch Pharm (Weinheim); 2016 Feb; 349(2):112-23. PubMed ID: 26701662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
    Parodi A; Righetti G; Pesce E; Salis A; Tasso B; Urbinati C; Tomati V; Damonte G; Rusnati M; Pedemonte N; Cichero E; Millo E
    Eur J Med Chem; 2020 Dec; 208():112833. PubMed ID: 32971410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
    Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
    Eur J Med Chem; 2018 Jan; 144():179-200. PubMed ID: 29272749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
    Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
    J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
    Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
    Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
    Laselva O; Molinski S; Casavola V; Bear CE
    Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
    Vaccarin C; Veit G; Hegedus T; Torres O; Chilin A; Lukacs GL; Marzaro G
    J Med Chem; 2024 Aug; 67(16):13891-13908. PubMed ID: 39137389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121.
    Kolski-Andreaco A; Taiclet S; Myerburg MM; Sembrat J; Bridges RJ; Straub AC; Wills ZP; Butterworth MB; Devor DC
    J Clin Invest; 2024 Jul; 134(16):. PubMed ID: 38954478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors.
    Righetti G; Casale M; Liessi N; Tasso B; Salis A; Tonelli M; Millo E; Pedemonte N; Fossa P; Cichero E
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.
    Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR
    Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.